Sensitive cell‑free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study

Le résumé fourni par la source

) status available for analysis, and 198 patients had both RAS and BRAF statuses available. Overall, the study confirmed the feasibility of liquid biopsy, achieving a concordance rate of 83.2% for RAS mutations and 82.3% for RAS and BRAF mutations when compared with tissue biopsy. The sensitivity of liquid biopsy for detecting RAS mutations was 77.3%, with a specificity of 94.3%. For RAS and BRAF mutations combined, the sensitivity was 77.0% and the specificity was 93.7%. Further analysis based on patient characteristics at the time of blood sampling showed higher sensitivity in chemotherapy-naive patients (sensitivity, 86.1%; specificity, 91.3%) and in patients with liver metastases (sensitivity, 88.6%; specificity, 89.7%). Sensitivity was also higher when the primary tumour was present (sensitivity, 88.6%) and in cases of disease progression or recurrence (sensitivity, 82.8%). In conclusion, liquid biopsy was a feasible and valuable method for detecting RAS and BRAF mutations in patients with mCRC, offering a less invasive alternative to traditional tissue biopsy in real-world settings. The trial registration number is 2015-A01272-47/NCT02751177 (registered March 3, 2016).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.